In conclusion, our findings demonstrated that the 4-gene signature was a promising prognostic indicator with a good prospect of clinical application for HER-2 negative breast cancer patients receiving taxane-anthracycline combination therapy. The gene discussed is ERBB2; the disease is breast cancer.